Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for treatment of CIDP, results from Privigen Impact on Mobility and Autonomy (PRIMA), a prospective, open‐label...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkies, Ingemar S.J., van Schaik, Ivo N., Léger, Jean‐Marc, Bril, Vera, van Geloven, Nan, Hartung, Hans‐Peter, Lewis, Richard A., Sobue, Gen, Lawo, John‐Philip, Durn, Billie L., Cornblath, David R., De Bleecker, Jan L., Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Tackenberg, Björn, Mielke, Orell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2019
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594229/
https://www.ncbi.nlm.nih.gov/pubmed/30672091
http://dx.doi.org/10.1111/jns.12302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594229/
https://www.ncbi.nlm.nih.gov/pubmed/30672091
http://dx.doi.org/10.1111/jns.12302

Ejemplares similares